Allergan announces plans to build first Medical Aesthetics Innovation Center in Chengdu China
Allergan has announced plans to open its first Medical Aesthetics Innovation Center in Chengdu China in early 2019. The center, to be located at the High-Tech Zone of Chengdu, will feature a world-class training center for medical aesthetics healthcare professionals, as well as an education and product experience center for medical aesthetics consumers.
On September 19 at the 2018 Chengdu International Investment Summit, Allergan and the Chengdu government officially signed the cooperation agreement of the establishment of the Allergan Medical Aesthetics Innovation Center. With a total investment of more than 14.7million USD, the center is scheduled to open to the public in early 2019 and will train more than 3,000 medical aesthetics professionals every year, providing Chinese consumers with opportunities to experience Allergan’s innovative medical aesthetics products and globally-leading medical aesthetics treatments, satisfying consumer demands for a “beautiful and confident life."
Chengdu High-Tech Zone representative commented, “Following with the prosperity and development of national medical aesthetics industry, Chengdu’s medical aesthetics market has been enjoying rapidly rising demands, and increasing industrial competitiveness and influence. Our medical aesthetics market here is strengthened by our mature, sophisticated infrastructure and abundant resources for innovation. We will continue to leverage Chengdu’s geopolitical advantage as a central hub for the Belt and Road Initiative as it becomes the Capital of Medical Aesthetics, defining the medical aesthetics industry’s development. The Chengdu High-Tech Zone will always embrace international platforms with local roots like Allergan Innovation Center. Through partnered support in production, academic, and R&D, these platforms can contribute to a sustainable industrial ecology in Chengdu. Together with our partners, this strong atmosphere of innovation will help build Chengdu into China’s, and even the world’s Capital of Medical Aesthetics.”
Jason Smith, Allergan Senior Vice President and President of APAC MEA said, “Allergan’s rapid growth in China is linked to China’s growing economy, supportive government policies and growing consumer interest in medical aesthetics treatments. This strategic collaboration with Chengdu actively enables Allergan to fulfill its long-term commitment to China in the medical aesthetics field. In the future, we also plan to establish Allergan China Western Operation Center in Chengdu. We will continue working closely with the government, industry associations and medical aesthetics organizations to promote the overall development of China's medical aesthetics industry and contribute to China's economic development.”
With innovation as its driving force, Allergan has continuously introduced its leading medical aesthetics products and treatments, including Botox®, Juvederm®, and Natrelle® to China. In addition to excellent products, Allergan has also introduced the world’s leading facial rejuvenation solutions to China, such as MD CodesTM and MD ASA™, which support medical aesthetics doctors to satisfy Chinese consumers’ personalized demands for scientifically-proven and safe medical aesthetics services.
Allergan China President White Wang commented, “Allergan’s rapid growth in China is driven by our desire to serve the market by continuously introducing innovative medical aesthetics products and technologies. Our Medical Aesthetics Innovation Center will allow close collaboration with the Chengdu government to explore how to accelerate the market access of innovative medical aesthetics products.”
The innovation center will make use of Allergan’s abundant innovative resources and extensive clinical experience from around the world to improve the consultation and treatment skills of Chinese medical aesthetics professionals and their clinics’ management levels. This will drive high service standards and high-quality outcomes for consumers, unlocking new momentum for China’s medical aesthetics industry.
At present, China's medical aesthetics industry is showing explosive growth. In 2018, the scale of China’s medical aesthetics market could reach 13.6 billion USD with the average growth rate of 22.7% from 2015 to 2020[1]. Under these circumstances, China’s medical aesthetics professionals are presently unable to meet the market demand neither in quantity nor in quality. In addition, there is a lack of professional and systematic medical aesthetics professionals training in the China market, which has become an important factor behind the scarcity of qualified professionals.
As Chinese society develops into a new era, meeting its people's increasing needs for a better life and achieving high-quality growth have become the main theme of China's economic development. The medical aesthetics industry’s growth represents this focus and is primed to reach new heights in its consumption capacity, thanks to its frequent product innovation and increased consumer appetite for personalized, experience-driven treatment. Medical aesthetics consumers have become more sophisticated in their awareness and selection of medical aesthetics services, devoting more attention to the added value of innovation on top of safe, effective products.
Since entering China in 2009, Allergan provides world-class academic exchange platforms for medical aesthetics professionals through the Allergan Medical Institution (AMI). In addition, Allergan is dedicated to improving the diagnosis and treatment skills of Chinese medical aesthetics professionals, so that Allergan products can be better leveraged in serving consumers. Following the establishment of the innovation center, Allergan will continue to join hands with a wide range of industry partners, such as medical institutions and regulatory authorities, to support seminars, international academic visits, online meetings, on-site practice and demonstrations, so as to enable more Chinese medical aesthetics professionals to master the world's leading diagnosis and treatment skills and concepts of medical aesthetics.
Data reference:
1: Deloitte's “China’s Medical Aesthetics Market Analysis 2017” report
